Equities research analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will announce earnings of $0.47 per share for the current quarter, Zacks reports. Six analysts have issued estimates for Endo International’s earnings. The lowest EPS estimate is $0.40 and the highest is $0.52. Endo International posted earnings per share of $0.76 in the same quarter last year, which would suggest a negative year-over-year growth rate of 38.2%. The business is expected to issue its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Endo International will report full-year earnings of $2.17 per share for the current financial year, with EPS estimates ranging from $2.10 to $2.25. For the next year, analysts anticipate that the company will report earnings of $2.41 per share, with EPS estimates ranging from $1.72 to $3.15. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.11. The business had revenue of $720.00 million during the quarter, compared to the consensus estimate of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.67 earnings per share.
Institutional investors have recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its holdings in shares of Endo International by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after buying an additional 1,397 shares during the last quarter. Piedmont Investment Advisors Inc. lifted its holdings in shares of Endo International by 3.5% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 47,942 shares of the company’s stock valued at $350,000 after purchasing an additional 1,607 shares in the last quarter. Mason Street Advisors LLC lifted its holdings in shares of Endo International by 3.4% in the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after purchasing an additional 2,134 shares in the last quarter. Neuburgh Advisers LLC lifted its holdings in shares of Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares in the last quarter. Finally, Comerica Bank lifted its holdings in shares of Endo International by 2.1% in the first quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after purchasing an additional 4,001 shares in the last quarter. 93.59% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:ENDP traded down $0.42 during trading on Friday, hitting $4.05. The company’s stock had a trading volume of 4,215,375 shares, compared to its average volume of 4,043,536. The company has a market cap of $916.04 million, a price-to-earnings ratio of 1.40 and a beta of 1.35. Endo International has a fifty-two week low of $4.02 and a fifty-two week high of $18.50.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Further Reading: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.